Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA clarifies pre-emption on OTC labeling

You may also be interested in...



J&J Directors Find Root Causes But Little Blame For OTC Quality Issues

A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.

Merck's Frazier Promoted To CEO To Drive Post-Schering Success

Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.

On Pre-emption, OTC Rule Among Signs Tipping Obama Administration’s Hand

FDA has not altered its support of pre-emption in product liability suits but there are signs it will happen under the Obama administration

UsernamePublicRestriction

Register

PS105343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel